Company expands generic warfarin recall to other product lines
A recent recall of generic warfarin tablets was expanded to include 6 other drug products prepared on the same packaging line.
A recent recall of generic warfarin tablets was expanded to include 6 other drug products prepared on the same packaging line.
The manufacturer, Upsher-Smith Laboratories, added to the recall 28 lots of 16 different products packaged from May 17, 2010, to November 17, 2010, in addition to the NDC# 0832-1214-00 lot with an expiration date of September 2012.
Products in the recall include:
- Amantadine 100 mg, 100-count bottles
- Amlodipine 5 mg, 90-count bottles
- Androxy 10 mg, 100-count bottles
- Baclofen 10 mg, 90-count bottles
- Bethanechol 5, 10, and 25 mg, 100-count bottles
- Jantoven 1, 2, 2.5, 3, 4, 5, 6, 7.5, and 10 mg, 100-count bottles
- Oxybutynin 5 mg, 100-count
Only a single batch of 3 mg Jantoven was included in the initial recall after 10 mg tablets were found in a 3 mg bottle sold at a retail pharmacy. Upsher-Smith said that affected products from both recalls were distributed to wholesalers, retailers, and independent pharmacies throughout the country. The company has informed customers and wholesalers that it will arrange for the return of any product involved in the recall.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More
